The first Tuesday of each month from 4-6 pm Arizona time, except for holiday weekends, ACMI will have a featured guest to discuss a relevant Behavioral Health topic; after the speaker, we will discuss current issues with the Behavioral Health System attendees. This month, come hear about Assertive Community Teams (ACT). We have Mercy Care discussing ACT teams and checkbox items and measurements. We have both Valleywise and CopaHealth describing their ACT team services.

Dr. Darling is the current medical director and psychiatrist for the Valleywise Health Assertive Community Treatment program. She has been in this role since graduating from her psychiatry residency in 2017. She is core faculty with the Creighton University Arizona Health Education Alliance Psychiatry Residency Program and faculty with the departments of psychiatry at The University of Arizona College of Medicine Phoenix, Mayo Clinic College of Medicine and Science Phoenix, and Creighton University College of Medicine. Dr. Darling completed her undergraduate education in psychology at Arizona State University in 2004. She then worked in case management for the outpatient SMI system in Maricopa County before attending medical school at Midwestern University Arizona College of Osteopathic Medicine. She completed her psychiatry residency training at Maricopa Integrated Health System in 2017. During her residency, she served as the chief resident for two years and was the Arizona Psychiatric Society resident of the year in 2017. Dr. Darling is board certified by the American Board of Psychiatry and Neurology, with a primary focus on treating refractory serious mental illness. In addition to her clinical work, Dr. Darling trains Creighton Alliance PGY3 psychiatry residents, hosts Creighton Alliance family medicine residents during their psychiatry rotation, and supervises 4th-year medical students on psychiatry rotations. She teaches two didactic courses for the Creighton Alliance residents, covering community resources for PGY1 residents and advanced psychopharmacology for PGY3 and PGY4 residents. Dr. Darling is involved in mentoring current residents and received the Howard E Wulsin Excellence in Teaching Award from the Arizona Psychiatric Society in 2022.

Dr Winona Z Belmonte, MD, is a board-certified psychiatrist.  She is the Asst Medical Director for ACT Services and Chief Psychiatrist for Metro Clinic of Copa Health. She is a product of the University of Virginia   Health Systems at Charlottesville, Virginia, where she graduated in psychiatric medicine with subspecialty/fellowship training in geriatric psychiatry.   She accepted a position to serve the full spectrum of psychiatric practice in the rural underserved areas of Virginia for three years. Challenging as it was, the experience galvanized her knowledge and acumen in clinical work and deepened her passion to provide the best service to those struggling with mental illness.  This passion took her to Phoenix, where she saw an opportunity to provide services in an environment where a team-based approach to care is alive.  She has served under multiple RBHA in Maricopa County since 2005 in various capacities but mostly as chief psychiatrist of clinics and Assertive Community Treatment psychiatrist. She was the first Medical Director of People of Color Network.  She is a dedicated psychiatrist with extensive experience in complex psychopharmacology and complicated social determinants of health issues.  

Blythe FitzHarris, P.h.D., LCSW is the Chief Clinical Officer at MercyCare and is responsible for clinical program development, including Adult and Children’s Systems of Care and the Central Region Behavioral Health Crisis System. Blythe oversees multiple Mercy Care service delivery systems, including integrated care, the Office of Individual and Family Affairs (OIFA), grant services, cultural diversity, and tribal affairs. She directs initiatives, strategies, and programs to address social determinants of health (such as housing and employment) and system performance. Blythe also oversees coordination of care with system stakeholders such as the Arizona Department of Economic Security and the Arizona Department of Justice and works closely with system advocates. She works across the organization to address member, family, provider, and/or contractor concerns to ensure positive clinical outcomes, care coordination, and quality service delivery. Previously, Blythe served as the Adult Systems of Care Administrator for Mercy Care. In this position, Blythe oversaw the Adult SMI System of Care, which included outpatient behavioral health services, Assertive Community Treatment, housing, rehabilitation, and employment services for members in Maricopa County and parts of Pinal County. She also served as Mercy Care’s lead for the Arnold v. Sarn settlement agreement. Blythe has more than 30 years of experience working in public behavioral health in a variety of clinical and operational positions and has taught social work at the university level.   Blythe is a licensed clinical social worker and has a master’s in social work and a Ph.D. in social welfare with a focus on mental health and recovery from Arizona State University.

Topic: ACMI Stakeholder’s Meeting

Time: June 6th, 2023 04:00 PM Arizona

Every month on the First Tuesday until December 25th, 2023,

July 11th, 2023, 04:00 PM – Population Health- interventions for high Utilizers, Dr. Mike Franczak

August 1st, 2023, 04:00 PM Dental- Brighter Way, Kris Volcheck

Sept 12th, 2023,  04:00 PM Hom Inc

Please download and import the following iCalendar (.ics) files to your calendar system.

Monthly: https://us02web.zoom.us/meeting/tZIudu6vqDspHdaOPI66YyVO1EYY3UYrWtCI/ics?icsToken=98tyKuGurTotHdKVsx6FRpwAA4j4KO3wpmJegqdcsy_MVXZqezXZZ8d7C-FKKcrn

Join Zoom Meeting

https://us02web.zoom.us/j/86317760372?pwd=MUJLZnl3cTFqSDRrbllmOUI0Sk82Zz09

Meeting ID: 863 1776 0372

Passcode: 795774

One tap mobile

+16699006833,,86317760372#,,,,*795774# US (San Jose)

+12532158782,,86317760372#,,,,*795774# US (Tacoma)

Dial by your location

        +1 669 900 6833 US (San Jose)

        +1 253 215 8782 US (Tacoma)

        +1 346 248 7799 US (Houston)

        +1 312 626 6799 US (Chicago)

        +1 929 205 6099 US (New York)

        +1 301 715 8592 US (Washington DC)

Meeting ID: 863 1776 0372

Passcode: 795774

Find your local number: https://us02web.zoom.us/u/kc1xiBw0Jl

Secure residential
Secure residential

Introduction:

Serious mental illnesses can be highly debilitating, affecting individuals’ ability to function in society and diminishing their quality of life. It is imperative to recognize the significance of secure facilities as essential tools for providing comprehensive care to those suffering from such conditions. By establishing secure facilities that prioritize treatment, insight, and rehabilitation, we can empower individuals with serious mental illness to gain invaluable insight into their conditions and facilitate their successful reintegration into the community. In this essay, we will explore the compelling arguments supporting the need for secure facilities as vital components of mental healthcare.

Safe and Controlled Environment:

Secure facilities offer a structured and controlled environment, ensuring the safety and well-being of individuals with serious mental illness. These environments provide a supportive framework to prevent self-harm, protect patients from external harm, and maintain a stable routine conducive to healing. By removing external stressors and triggers, secure facilities allow individuals to focus solely on their recovery journey, ultimately enhancing their chances of gaining insight into their illness.

Comprehensive Treatment and Rehabilitation:

Secure facilities are uniquely equipped to provide comprehensive treatment and rehabilitation programs tailored to the specific needs of individuals with serious mental illness. These facilities often employ a multidisciplinary approach involving psychiatrists, psychologists, therapists, and other mental health professionals. Through evidence-based therapies, medication management, counseling, and skill-building workshops, individuals can develop coping mechanisms, increase self-awareness, and acquire essential life skills. This comprehensive treatment approach empowers individuals to manage their conditions effectively and take steps towards reintegrating into the community.

Insight into Illness:

Secure facilities create an environment that encourages self-reflection, insight, and understanding of one’s mental illness. Through therapy sessions, group discussions, and educational programs, individuals can gain a deeper understanding of the causes, symptoms, and impact of their condition. This insight is a crucial stepping stone towards accepting their illness, embracing treatment, and making informed decisions about their recovery journey. By fostering self-awareness and providing psychoeducation, secure facilities empower individuals to actively participate in their own healing process.

Stigma Reduction and Community Reintegration:

Secure facilities play a pivotal role in combating the stigma surrounding mental illness and fostering community reintegration. By providing individuals with the tools to manage their conditions, secure facilities empower them to challenge societal misconceptions and stereotypes. The supportive environment within these facilities allows patients to practice and develop social skills, rebuild relationships, and establish a support network. As individuals gain insight into their illness and demonstrate progress, they are better equipped to reintegrate into the community, fostering understanding, empathy, and acceptance among society at large.

Long-term Benefits and Cost-effectiveness:

Investing in secure facilities for serious mental illness yields long-term benefits and is a cost-effective strategy for society as a whole. By providing intensive treatment and support, these facilities can reduce the frequency and severity of relapses, emergency room visits, and hospitalizations. As individuals gain insight, acquire coping skills, and reintegrate into the community, they are more likely to become productive members of society, contributing to the workforce, and reducing reliance on disability benefits. Furthermore, the overall economic burden of untreated mental illness, including lost productivity and increased healthcare costs, can be mitigated through early intervention and comprehensive treatment within secure facilities.

Conclusion:

The establishment of secure facilities for individuals with serious mental illness is an essential aspect of a compassionate and effective mental healthcare system. By providing a safe and structured environment, comprehensive treatment, insight into illness, and opportunities for community reintegration, secure facilities empower individuals to reclaim their lives and realize their full potential. Investing in these facilities not only benefits the individuals themselves but also society as a whole, promoting well-being, reducing stigma, and fostering a more inclusive and understanding community.

Thank you to those who could attend our May 2nd Stakeholder’s meeting.

Rachel Streiff, Dr. Robert Laitman, and Dr. Ann Mandel presented.

Below are the links to the webinar and slides:

Webinars – Association for the Chronically Mentally Ill (ACMI) (acmionline.com)

Downloads – Association for the Chronically Mentally Ill (ACMI) (acmionline.com)

Please join us for our next informational event on June 6th, 2023, at 4 PM AZ time. Experts will be discussing Assertive Community Treatment teams. (ACT)

ZOOM ACCESS INFORMATION:

https://us02web.zoom.us/j/86317760372?pwd=MUJLZnl3cTFqSDRrbllmOUI0Sk82Zz09

Meeting ID: 863 1776 0372 . . . . . . . . Passcode: 795774

One tap mobile +16699006833,,86317760372#,,,,*795774# US (San Jose)

Dial by your location +1 669 900 6833 US (San Jose)  + 1 253 215 8782 US (Tacoma)

The first Tuesday of each month from 4-6 pm Arizona time, except for holiday weekends, ACMI will have a featured guest to discuss a relevant Behavioral Health topic; after the speaker, we will discuss current issues with attendees with the Behavioral Health System.

This month, come hear about Innovations in Clozapine Therapy with SMI advocate Rachel Streiff and special guests Dr. Robert Laitman and Dr. Ann Mandel.

Dr. Robert Laitman practices internal psychiatric medicine in New York City alongside his wife, Dr. Ann Mandel Laitman, and is a co-author of “Meaningful Recovery From Schizophrenia and Serious Mental Illness with Clozapine: Hope and Help.”

Rachel Streiff is a chemical and biomedical engineer who became an advocate for families struggling with Serious Mental Illness after a member of her own family achieved recovery.

…………………………………………………………………………….

Topic: ACMI Stakeholder’s Meeting

Time: May 2nd,, 2023 04:00 PM Arizona

Every month on the First Tuesday until December 25th, 2023,

June 6th, 2023, 04:00 PM

July 11th, 2023, 04:00 PM

August 1st, 2023, 04:00 PM

Please download and import the following iCalendar (.ics) files to your calendar system.

Monthly: https://us02web.zoom.us/meeting/tZIudu6vqDspHdaOPI66YyVO1EYY3UYrWtCI/ics?icsToken=98tyKuGurTotHdKVsx6FRpwAA4j4KO3wpmJegqdcsy_MVXZqezXZZ8d7C-FKKcrn

Join Zoom Meeting

https://us02web.zoom.us/j/86317760372?pwd=MUJLZnl3cTFqSDRrbllmOUI0Sk82Zz09

Meeting ID: 863 1776 0372

Passcode: 795774

One tap mobile

+16699006833,,86317760372#,,,,*795774# US (San Jose)

+12532158782,,86317760372#,,,,*795774# US (Tacoma)

Dial by your location

        +1 669 900 6833 US (San Jose)

        +1 253 215 8782 US (Tacoma)

        +1 346 248 7799 US (Houston)

        +1 312 626 6799 US (Chicago)

        +1 929 205 6099 US (New York)

        +1 301 715 8592 US (Washington DC)

Meeting ID: 863 1776 0372

Passcode: 795774

Find your local number: https://us02web.zoom.us/u/kc1xiBw0Jl

The first Tuesday of each month from 4-6 pm Arizona time, except for holiday weekends, ACMI will have a featured guest that will discuss a relevant Behavioral Health topic; after the speaker, we will have discussions with attendees on current issues with the Behavioral Health System.

Housing in Arizona for SMI & GMH/SA- What are the plans for the H2O waiver implementation? AHCCCS plans for Housing

David Bridge is the Special Needs Program Administrator for the Arizona Department of Housing. He will talk about the H2O waiver which addresses housing for homeless and General Mental Health/ Substance Use (GMH/SU) and Serious Mental Illness (SMI) members. Also, what is the H2O waiver?

Alex Demyan, Interim Assistant Director, Arizona Health Care Cost Containment System (AHCCCS), and Elizabeth da Costa, Housing Program Administrator, Arizona Health Care Cost Containment System (AHCCCS) will answer questions that were pre-submitted:

  • What are the goals for this H2O waiver?
  • Can you talk about what the current need is for housing units of various types?
  • Can you talk about the current and predicted number of vouchers?
  • How is Hom Inc related to this initiative, will they manage the transitional housing as well?
  • How will people waiting for housing be prioritized for housing?  
  • What is the plan to get the people Permanent supportive housing (PSH) after the six months of transitional housing ends?
  • If someone gets six months of transitional housing and then does not get PSH are they again eligible if they become homeless for another six months of transitional housing?

This is an important topic as we believe housing is an essential part of healthcare.

Topic: ACMI Stakeholder’s Meeting

Time: March 7th, 2023 04:00 PM Arizona

Every month on the First Tuesday until December, 25th, 2023,

April 4th, 2023 04:00 PM

May 6th, 2023 04:00 PM

June 6th, 2023 04:00 PM

July 11th, 04:00 PM

August 1st, 04:00 PM

Please download and import the following iCalendar (.ics) files to your calendar system.

Monthly: https://us02web.zoom.us/meeting/tZIudu6vqDspHdaOPI66YyVO1EYY3UYrWtCI/ics?icsToken=98tyKuGurTotHdKVsx6FRpwAA4j4KO3wpmJegqdcsy_MVXZqezXZZ8d7C-FKKcrn

Join Zoom Meeting

https://us02web.zoom.us/j/86317760372?pwd=MUJLZnl3cTFqSDRrbllmOUI0Sk82Zz09

Meeting ID: 863 1776 0372

Passcode: 795774

One tap mobile

+16699006833,,86317760372#,,,,*795774# US (San Jose)

+12532158782,,86317760372#,,,,*795774# US (Tacoma)

Dial by your location

        +1 669 900 6833 US (San Jose)

        +1 253 215 8782 US (Tacoma)

        +1 346 248 7799 US (Houston)

        +1 312 626 6799 US (Chicago)

        +1 929 205 6099 US (New York)

        +1 301 715 8592 US (Washington DC)

Meeting ID: 863 1776 0372

Passcode: 795774 Find your local number: https://us02web.zoom.us/u/kc1xiBw0Jl

The first Tuesday of each month from 4-6 pm Arizona time, except for holiday weekends, ACMI will have a featured guest that will discuss a relevant Behavioral Health topic; after the speaker, we will have discussions with attendees on current issues with the Behavioral Health System.

Housing in Arizona for SMI & GMH/SA- What are the plans for the H2O waiver implementation? AHCCCS plans for Housing

David Bridge is the Special Needs Program Administrator for the Arizona Department of Housing. He will talk about the H2O waiver which addresses housing for homeless and General Mental Health/ Substance Use (GMH/SU) and Serious Mental Illness (SMI) members. Also, what is the H2O waiver? Alex Demyan, Interim Assistant Director, Arizona Health Care Cost Containment System (AHCCCS), and Elizabeth da Costa, Housing Program Administrator, Arizona Health Care Cost Containment System (AHCCCS) will answer questions that were pre-submitted:

  • What are the goals for this H2O waiver?
  • Can you talk about what the current need is for housing units of various types?
  • Can you talk about the current and predicted number of vouchers?
  • How is Hom Inc related to this initiative, will they manage the transitional housing as well?
  • How will people waiting for housing be prioritized for housing?  
  • What is the plan to get the people Permanent supportive housing (PSH) after the six months of transitional housing ends?
  • If someone gets six months of transitional housing and then does not get PSH are they again eligible if they become homeless for another six months of transitional housing?

This is an important topic as we believe housing is an essential part of healthcare.

Topic: ACMI Stakeholder’s Meeting

Time: March 7th, 2023 04:00 PM Arizona

Every month on the First Tuesday until December, 25th, 2023,

April 4th, 2023 04:00 PM

May 6th, 2023 04:00 PM

June 6th, 2023 04:00 PM

July 11th, 04:00 PM

August 1st, 04:00 PM

Please download and import the following iCalendar (.ics) files to your calendar system.

Monthly: https://us02web.zoom.us/meeting/tZIudu6vqDspHdaOPI66YyVO1EYY3UYrWtCI/ics?icsToken=98tyKuGurTotHdKVsx6FRpwAA4j4KO3wpmJegqdcsy_MVXZqezXZZ8d7C-FKKcrn

Join Zoom Meeting

https://us02web.zoom.us/j/86317760372?pwd=MUJLZnl3cTFqSDRrbllmOUI0Sk82Zz09

Meeting ID: 863 1776 0372

Passcode: 795774

One tap mobile

+16699006833,,86317760372#,,,,*795774# US (San Jose)

+12532158782,,86317760372#,,,,*795774# US (Tacoma)

Dial by your location

        +1 669 900 6833 US (San Jose)

        +1 253 215 8782 US (Tacoma)

        +1 346 248 7799 US (Houston)

        +1 312 626 6799 US (Chicago)

        +1 929 205 6099 US (New York)

        +1 301 715 8592 US (Washington DC)

Meeting ID: 863 1776 0372

Passcode: 795774 Find your local number: https://us02web.zoom.us/u/kc1xiBw0Jl

Dr. Christopher J. Smith is an experimental psychologist with expertise in diagnosing autism spectrum disorder and measuring associated traits. Dr. Smith oversees all diagnostic evaluations and assessments for our clients while also directing all internal and external research projects. Prior to joining us at SARRC, he worked as an assistant professor in the Department of Psychiatry at the Mount Sinai School of Medicine, where he still maintains a faculty position. Originally drawn to study autism because of the complexity of the disorder, here at SARRC, Dr. Smith values the ability to work with clients across all age groups and engage in out-of-the-box research endeavors.

EDUCATION
  • B.S. Psychology
    East Stroudsburg University
  • M.A. Experimental Psychology
    CUNY, Graduate School: Brooklyn College
  • Ph.D. Experimental Psychology
    CUNY, Graduate School: Brooklyn College

Here are the links to the slides and the webinar. You need to sign up for an account to access the restricted content. Accounts are free.

Autism in Adults Dr Christopher Smith  https://acmionline.com/?smd_process_download=1&download_id=8870

Autism defined by Dr Christopher Smith

Please read the latest report on Reimage Schizophrenia: transforming how we are treated function and thrive.

Published from the Schizophrenia & Psychosis Alliance, the summary of findings published Feb 2023.

BREAKING! Click here to read our new Voice of the Patient Report (https://sczaction.org/insight-initiative/pfdd/), which captures the powerful stories of people living with schizophrenia and those who care for them. The report summarizes the compelling testimony provided during our Externally-Led Patient-Focused Drug Development meeting on Nov. 2, and was submitted today to the U.S. Food and Drug Administration.

The meeting gave our community a voice – and it was heard. FDA’s Dr. Bernard Fischer told us during the meeting that “the FDA recognizes that there is more work to be done to get better treatments for schizophrenia.”

We thank our meeting co-hosts, who joined us to provide a united front in the fight for treatment equity for people living with schizophrenia: American Foundation for Suicide Prevention, Mental Health America, National Council for Mental Wellbeing and NAMI. And we are indebted to the people living with schizophrenia and their caregivers who participated in this effort and made their voices heard.

People with schizophrenia have the right to effective medicines – just like anyone else with a serious disease. We are working every day to make that happen.


Executive summary

Schizophrenia is a serious, disabling brain disease. While medical treatment for schizophrenia has existed for many years, these treatments are often ineffective and can cause debilitating side effects. The result: countless people with this severe brain disease are subjected to a trial-and-error approach, switching from one medicine to another in hopes of finding something that will curb what can be disabling and life-disrupting symptoms.

Many people with schizophrenia have yet to find a medicine that works for them — creating an entire population of people who cannot
work or live independently and can suffer devastating symptoms of psychosis that can lead to incarceration or homelessness. Just as with
heart disease, diabetes or any other serious illness, if schizophrenia isn’t treated properly, it can get progressively worse. With the goal of turning the tide and improving drug-treatment options for schizophrenia, people with the brain disease and their caregivers gathered virtually on November 2, 2022, to describe what it’s like to live with this serious disease and share their experiences with available drug treatments.
Participants not only pressed drug developers to intensify efforts to develop more effective drug treatments with fewer side effects— they also urged the U.S. Food and Drug Administration (FDA) to allow broader access to the “last resort” drug clozapine, which many patients credited with restoring their ability to attend school, work and live healthy and productive lives.

The meeting, “Reimagine Schizophrenia: Transforming How We Are Treated, Function and Thrive,” was co-hosted by the Schizophrenia & Psychosis Action Alliance, the American Foundation for Suicide Prevention, Mental Health America, the National Alliance on Mental Illness and the National Council for Mental Wellbeing as part of the FDA’s Externally-Led Patient-Focused Drug Development (PFDD) initiative. The FDA launched this initiative in 2012 to collect information about patient and caregiver perspectives on drug development — in particular, what people living with a disease consider to be meaningful treatment benefits and how they want to be involved in the drug development process.

Many people with schizophrenia have yet to find a medicine that works for them — creating an entire population of people who cannot work or live independently and can suffer devastating symptoms of psychosis.

Advocates across the country are fighting against barriers to healthcare for people seeking mental health treatment. The IMD exclusion (explanation in the OP-ED) continues to eliminate the stability period that is necessary for many people with serious mental illness. Let’s continue to ask for reforms to the IMD exclusion rule; waivers are not enough.

Laurie Goldstein- ACMI Vice President

Congress must stop blocking mental health clinics from needed money

By Cheryl Roberts

New York Daily News

Jan 24, 2023 at 5:00 am

Newly elected Congressman Dan Goldman’s announcement about reintroducing the Michelle Alyssa Go Act is welcomed news. The Act, named after Michelle Go, the young woman pushed to her death in front of a subway train by Martial Simon, a homeless man with serious mental illness, would amend the decades old federal rule at the root of our broken mental health system.

The Institutions of Mental Disease or “IMD Rule” was enacted in 1965 as part of the Social Security Act and denies Medicaid to patients admitted to psycho-therapeutic facilities with more than 16 beds including hospitals, nursing homes and community or so-called congregate care facilities. By restricting federal Medicaid dollars to small residential institutions, Congress rightly figured that service providers would never achieve “scale,” making it impossible for IMD providers to break even, let alone make a responsible profit.

Instead, Congress hoped that by funding community services and eliminating large asylums, poor people with serious mental illness would be served elsewhere, and they have been — in prisons, jails and at the undertakers.

Michelle Go (left) and Martial Simon
Michelle Go (left) and Martial Simon

The need for more psychiatric beds whether in-patient or congregate care, is an uncomfortable fact that some would rather ignore, a luxury not possible for parents like Teresa and Dan Pasquini, sisters like Hilary de Vries, or members of Michelle Go’s family.

Like it or not, some people living with serious mental illness would do better having access to financially viable, reasonably sized congregate care residential facilities located close to family and loved ones. Yet for many people, this community-based option has been off the table for nearly 60 years because of the IMD Rule. Without this option and others, including in-patient hospitalization and residential facilities where residents are not completely at liberty to come and go, the much heralded “continuum of care” is not achievable, at least not for everyone.

There is no better proof of this reality and the need for a range of such facilities, than the fact that over the same time period, many of these options have been available to those who can afford private pay residential and in-patient facilities. This reality demonstrates that IMDs above 16 beds are not inherently bad, we just don’t want to pay for good ones, at least not for poor people. Instead, we have stood by and watched as our prisons and jails filled up with poor people living with mental illness, especially Black and Brown people, who landed in the criminal justice system after the mental health system failed them, their loved ones and the innocent victims and their families.

Ironically, in the end, the IMD fundamentally undercut the gold standard of our mental health care system: ensuring access to community-based mental health services as part of a broad continuum of care. By drawing a crude line in the sand at 16 beds for all IMDs, Congress over-simplified both the problem and the solution needed to address the very real concerns associated with the large, underfunded snake-pit mental health asylums of old.

As Goldman reintroduces legislation to amend the IMD Rule, rather than seeking a wholesale repeal of the rule, the amendments should be drawn with more precision. Otherwise, not only will complete repeal of the IMD be dead on arrival due to its high cost, it will also unnecessarily raise real concerns about the government’s ability to control very large scale asylums and prevent some of the abuses of the past.

Rather, instead of once again taking a crude, one size fits all approach to Medicaid funding for mental health treatment, Congress should create different bed limitations for different kinds of facilities. For example, members might find that 36-bed congregate care facilities would be both humane for clients and financially viable for service providers. Similarly, raising the legal bed capacity for in-patient psychiatric hospitals to 100 or 150 might enable New York City’s public Health + Hospitals to offer high quality, safe, therapeutic and humane options for New Yorkers in need of that level of care.

Not only would extending the continuum of care be the humane option for those living with serious mental illness and their families, but it would also improve public safety and save money by preventing people with serious mental illness from entering into the criminal justice system in the first place.

It’s time for Congress to get this one right. To be thoughtful but to delay no longer. Michelle Go and Martial Simon deserved better, so did their loved ones.

Roberts is a part-time City Court judge in Hudson, N.Y., where she presides over the Mental Health Court and is the executive director of the Greenburger Center for Social and Criminal Justice.

The first Tuesday of each month from 4-6 pm Arizona time, except for holiday weekends, ACMI will have a featured guest that will discuss a relevant Behavioral Health topic; after the speaker, we will have discussions with attendees on current issues with the Behavioral Health System.

“Autism in Adults: What does that look like, and what to do about it” by Dr. Christopher Smith

Dr. Christopher J. Smith is an experimental psychologist with expertise in diagnosing autism spectrum disorder and measuring associated traits. Dr. Smith oversees all diagnostic evaluations and assessments for our clients while also directing all internal and external research projects. Prior to joining us at SARRC, he worked as an assistant professor in the Department of Psychiatry at the Mount Sinai School of Medicine, where he still maintains a faculty position. Originally drawn to study autism because of the complexity of the disorder, here at SARRC, Dr. Smith values the ability to work with clients across all age groups and engage in out-of-the-box research endeavors.

Topic: ACMI Stakeholder’s Meeting

Time: February 7th,, 2023 04:00 PM Arizona

Every month on the First Tuesday until December, 25th, 2023,

March 7th, 2023 04:00 PM

April 4th, 2023 04:00 PM

May 6th, 2023 04:00 PM

June 6th, 2023 04:00 PM

July 11th, 04:00 PM

August 1st, 04:00 PM

Please download and import the following iCalendar (.ics) files to your calendar system.

Monthly: https://us02web.zoom.us/meeting/tZIudu6vqDspHdaOPI66YyVO1EYY3UYrWtCI/ics?icsToken=98tyKuGurTotHdKVsx6FRpwAA4j4KO3wpmJegqdcsy_MVXZqezXZZ8d7C-FKKcrn

Join Zoom Meeting

https://us02web.zoom.us/j/86317760372?pwd=MUJLZnl3cTFqSDRrbllmOUI0Sk82Zz09

Meeting ID: 863 1776 0372

Passcode: 795774

One tap mobile

+16699006833,,86317760372#,,,,*795774# US (San Jose)

+12532158782,,86317760372#,,,,*795774# US (Tacoma)

Dial by your location

        +1 669 900 6833 US (San Jose)

        +1 253 215 8782 US (Tacoma)

        +1 346 248 7799 US (Houston)

        +1 312 626 6799 US (Chicago)

        +1 929 205 6099 US (New York)

        +1 301 715 8592 US (Washington DC)

Meeting ID: 863 1776 0372

Passcode: 795774 Find your local number: https://us02web.zoom.us/u/kc1xiBw0Jl